CFDA Pharmacopoeia Order Could Lead to Greater Import Testing
This article was originally published in PharmAsia News
Executive Summary
Foreign medicinal products entering China could face greater testing at customs ports and encounter potential hurdles - especially with regard to products not included in the revised Chinese Pharmacopoeia (ChP) - following the China Food and Drug Administration's recent notice reinforcing the applicability of ChP to all imported drugs.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.